Mesoblast (MEOBF) Cash & Equivalents Growth (1y) (2015 - 2026)
Powered by 
Analysis
Mesoblast (MEOBF) Cash & Equivalents Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 20.89% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -16.36% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -30.46% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 13.01% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 55.71% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | -36.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.30% |
| Dec 31, 2025 | 241.78% |
| Jun 30, 2025 | 156.59% |
| Dec 31, 2024 | -50.96% |
| Jun 30, 2024 | -11.72% |
| Dec 31, 2023 | 14.69% |
| Jun 30, 2023 | 17.98% |
| Mar 31, 2023 | -36.43% |
| Dec 31, 2022 | -28.71% |
| Sep 30, 2022 | -26.26% |
| Jun 30, 2022 | -55.84% |
| Mar 31, 2022 | -51.50% |
| Dec 31, 2021 | 22.34% |
| Sep 30, 2021 | 7.24% |
| Jun 30, 2021 | 5.84% |
| Mar 31, 2021 | 163.43% |
| Dec 31, 2020 | -4.70% |
| Sep 30, 2020 | 213.07% |
| Jun 30, 2020 | 156.47% |
| Mar 31, 2020 | -14.65% |